BACKGROUND: Postdiagnosis weight gain in patients with breast cancer has been associated with increased cancer recurrence and mortality. This study was designed to identify risk factors for weight gain and create a predictive model to identify a high-risk population for targeted interventions. METHODS: The weight of 393 patients with breast cancer from the Northwestern Robert H. Lurie Cancer Center was measured over a 2-year period from diagnosis, with body mass index (BMI) change over 18 months as the primary endpoint. Demographics, clinical factors, treatment methods, as well as tumor characteristics were also recorded; and a lifestyle questionnaire was conducted. Blood samples were genotyped for 16 single nucleotide polymorphisms in FTO, adiponectin pathway genes (ADIPOQ, ADIPOR1), and FNDC5. Serum leptin, adiponectin, and irisin levels also were measured. RESULTS: Mean 6 standard deviation 18-month BMI changes were 0.68 6 1.42, 0.98 6 1.62, 0.79 6 1.74, and 20.44 6 1.58 kg/m 2 for patients ages <40, 40 to 49, 50 to 59, and 60 years, respectively. The optimal multivariable model for 18-month BMI change contained the predictors age, height, and endocrine therapy, but only age was statistically significant, with a 0.04 kg/m 2 increase in 18-month BMI change per younger year of age. Single nucleotide polymorphisms in ADIPOR1, FTO, and FNDC5 were associated with 18-month BMI change, and the first 2 remained significant after adjusting for the optimal clinical model (all P < .05). CONCLUSIONS: Women age 60 years and younger at the time of breast cancer diagnosis who have an obesity genetic risk model are at increased risk for weight gain after treatment and should be targeted for weight-maintenance interventions. Cancer 2017;123:2413-21. V C 2017 American Cancer Society.
INTRODUCTION
Obesity has been associated with increased risk of developing breast cancer as well as increased breast cancer-related deaths. 1 It is thought that obesity increases breast cancer risk and risk of recurrence through an increase in estrogen, inflammation, and the development of metabolic syndrome. 2 Breast cancer survivors are at higher risk for developing metabolic syndrome/insulin resistance, 3 and insulin and adiponectin plasma levels at diagnosis have been correlated with breast cancer prognosis. 4, 5 Our previous work indicated that functional single nucleotide polymorphisms (SNPs) for obesity and metabolic syndrome-related genes (fat mass and obesity-associated gene [FTO] , adiponectin pathway genes) were significantly associated with breast cancer risk. [6] [7] [8] It has been demonstrated that patients with newly diagnosed breast cancer gain more weight than cancer-free women. 9 This weight gain has been associated with increased all-cause mortality, 10, 11 and several studies have pointed toward increased breast cancer-specific mortality. 12, 13 Several studies have assessed weight gain in breast cancer survivors, but the reasons underlying this weight gain remain unclear. The role of chemotherapy and receipt of tamoxifen in weight gain was evaluated in the Women's Healthy Eating and Living study; and, although chemotherapy was associated with weight gain, tamoxifen was not. 14 Other studies reported associations between age at diagnosis, tumor characteristics, menopausal status, and weight gain. 15, 16 We recently performed a retrospective study in 459 women with newly diagnosed breast cancer and observed that the factors associated with weight gain included genetic polymorphisms for obesity-related genes (FTO; adiponectin, C1Q, and collagen domain containing [ADIPOQ] ; adiponectin receptor 1 [ADIPOR1]), age at diagnosis, BMI at diagnosis, type of breast cancer, and receipt of adjuvant chemotherapy. 17 To our knowledge, that was the first study to evaluate the genetic and nongenetic factors associated with breast cancer-related weight gain.
On the basis of results from our retrospective study, 17 the objective of this study was to validate these findings in a prospectively collected cohort of patients with newly diagnosed breast cancer. More specifically, the role of demographic, treatment-related, metabolic, genetic, and lifestyle factors in breast cancer-associated weight gain was evaluated. Our goal was to identify a population of patients with breast cancer at higher risk for weight gain with intent to offer targeted interventions to prevent weight gain and subsequently improve their survival.
MATERIALS AND METHODS

Study Participants
Patients were recruited from the Medical Oncology Clinic at Robert H. Lurie Comprehensive Cancer Center from May 2009 to August 2014. All patients signed informed consent for study participation and genetic studies, and the protocol was approved by the Institutional Review Board of Northwestern University. Inclusion criteria were a diagnosis of stage I through III breast cancer, age 18 years, and female sex. Exclusion criteria were the presence of in situ only cancer, metastatic disease, pregnancy, or poorly controlled diseases that could independently result in weight changes, such as thyroid disease or systemic infection.
DNA Isolation
Blood samples were collected for genotyping of polymorphisms in FTO, ADIPOQ, ADIPOR1, and fibronectin type III domain-containing protein 5 (FNDC5). DNA from whole-blood lymphocytes was extracted using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and stored at 2208C until it was used for genotyping.
Selection of SNPs
We chose to genotype SNPs from genes implicated in obesity and insulin resistance (ADIPOQ, ADIPOR1, FTO, and FNDP5) based on our previously published data as well as their functional status. [6] [7] [8] [17] [18] [19] 
Genotyping
Genotyping for the 16 selected SNPs was performed by Taqman SNP allelic discrimination using an ABI 7900HT (Applied Biosystems, Forest City, Calif). Results were ascertained by using the SDS software package (version 2.3; Applied Biosystems). All results were automatically called (ie, the device displays the genotypes automatically with 95% certainty). In total, 5% of samples were genotyped in duplicate and exhibited 100% concordance.
Protein Measurement
Serum samples were prepared by centrifugation according to standard protocols, aliquoted, and stored at 2808C until assayed. Serum levels of leptin, adiponectin, and highmolecular-weight adiponectin were quantified in duplicate by corresponding enzyme-linked immunosorbent assays (EMD Millipore, St Charles, Mo) according to the manufacturer's instructions. Serum irisin levels were quantified in duplicate using a commercially available radioimmunoassay kit (Phoenix Pharmaceuticals, Burlingame, Calif) according to the manufacturer's instructions.
Statistical Analysis
Demographic, clinical, and treatment characteristics of the patients were summarized using averages (ranges) for continuous factors and counts (percentages) for categorical factors. For each patient, 18-month BMI change was defined as the difference between BMI at 18-months and baseline; and 24-month, 12-month, and 6-month BMI changes also were noted. After summarizing the characteristics, univariate normal linear regression was used to assess the association individually with each of the demographic, clinical, and treatment factors. An optimal predictive clinical multivariable model was constructed using a stepwise Akaike information criterion model search combined with the retention of statistically significant effects from the multivariable normal regression.
The same univariate and multivariable strategy was used to assess the association of SNPs with BMI change, using categorical coding with the 3 levels (1 copy of the major and minor allele [reference] vs 2 copies of the major allele vs 2 copies of the minor allele). An additional multivariable model for the clinical/demographic variables combined with SNPs was evaluated. An optimal linear mixed model for BMI was constructed using stepwise Akaike information criterion model selection based on demographic, clinical, and treatment factors. The association of 30 diet and lifestyle questionnaire results with BMI change over 18 months was assessed using univariate Original Article linear regression. Pearson correlations between baseline adiponectin, leptin, and irisin levels with 18-month BMI changes were assessed for a subset of patients who had marker measurements obtained at their final visit. Multivariable logistic regression was used to model the weight increase >0.5 kg/m 2 as well as a 5% increase in BMI. In our retrospective analysis, we observed a total weight change 6 standard deviation of 4.5 6 9.4 pounds. With 80% power and 2-sided a 5 .05, and assuming a standard deviation of 9.4 pounds for a change in weight from diagnosis for each group, we would be able to detect a difference as small as 3.0 pounds between the chemotherapy group (n 5 180) and the nonchemotherapy group (n 5 135). This is not as small as the difference observed in our retrospectively collected data. However, we anticipated that the standard deviation for weight change would be smaller in the prospectively measured data, because we would not rely on medical record data but on actual measured assessment. Therefore, our goal was to recruit 200 women in the chemotherapy group and 150 in the nonchemotherapy group. At the end of the 2-year follow-up period we anticipated that approximately 10% of women in each group would be lost to follow-up, breast cancer recurrence, or death. Therefore, our power was based on a total sample size of approximately 315 women (ie, 180 in the chemotherapy group and 135 in the nonchemotherapy group). All statistical tests were performed at the 2-sided .05 significance level, and all statistical analyses were performed with the R open statistical package (R Foundation for Statistical Computing, Austria, Vienna).
RESULTS
Baseline Characteristics
Of the 424 patients initially enrolled in the study, 31 were excluded for breast cancer recurrence, other cancers, other severe comorbidities, or pregnancy during follow-up. Table 1 provides the baseline patient characteristics, and 
Weight Gain
Patients tended to gain weight, and the propensity for a >0.5 kg/m 2 BMI gain increased over the study period, with 29.2%, 37.2%, 46.2%, and 50.3% of women reaching this gain over 6, 12, 18, and 24 months, respectively (Table 3 ). Figure 1 illustrates the distribution of 18-month BMI change according to age group, revealing that weight gains were more common among patients aged <60 years. The mean 6 standard deviation 18-month BMI changes were 0.68 6 1.42, 0.98 6 1.62, 0.79 6 1.74, and 20.44 6 1.58 kg/m 2 for patients ages <40, 40 to 49, 50 to 59, and 60 years, respectively.
Association of Demographic and Clinical Variables With 18-Month BMI Change
Of the characteristics considered, only age, menopause, and waist circumference at diagnosis had a statistically significant effect on 18-month BMI change, with greater weight gains among younger and premenopausal women who a had smaller waist circumference ( a 1-cm smaller waist circumference had a BMI change >0.02 kg/m 2 (95% CI, 0.00-0.04; P 5 .02), but waist circumference was not significantly associated with the risk of a 0.5 BMI increase. The optimal multivariable model for 18-month BMI change included age, height, and endocrine therapy, but only age was statistically significant, with a 0.04 increase in 18-month BMI change for every 1-year decrease in age; this model explained less than 10% of the variation in 18-month BMI change ( Table 5) .
Analysis of BMI Trends Over Time
Predictors of BMI change by month on study included age, BMI at diagnosis, chemotherapy, endocrine therapy, the interaction of height and month of enrollment, and the interaction of chemotherapy and month of enrollment (Table 6 ).
BMI increased on average 0.29 kg/m 2 with each increasing month of follow-up (95% CI, 0.06-0.52; P 5 .01), and BMI increased 0.03 kg/m 2 for each decrease in year of age (95% CI, 0.01-0.04; P < .001). Women who received endocrine therapy had 0.41 higher BMI compared with women who did not (95% CI, 0.05-0.78; P 5 .03). Women who received chemotherapy had 0.82 kg/m 2 lower BMI compared with women who did not receive chemotherapy (95% CI, 21.24 to 20.40; P < .001), but this effect decreased over time, as in the women who received chemotherapy, the BMI increase with increasing month of enrollment was 0.05 kg/m 2 per month larger compared with women who did not receive chemotherapy (95% CI, 0.03-0.07; P < .001). For taller women, the BMI increase with increasing month of enrollment was less pronounced. A woman who was 10 cm taller had a 0.02 kg/m 2 -lower BMI increase per month compared with a shorter woman (95% CI, 20.003 to 0.0003; P 5 .02).
Association of SNPs With 18-Month BMI Change
Of the 16 SNPs investigated, only 3 were statistically significantly associated with 18-month BMI change on univariate analysis in the genes ADIPOR1, FTO, and FNDC5 (P < .05 for all). These SNPs also were included in an optimized multivariable model (Table 7) to assess their independent predictive value. The model contained main effects for selected SNPs from all 3 genes in addition to an interaction between ADIPOR1 and FTO; however, only FTO and the interaction term remained statistically significant, and the percentage variation in 18-month BMI change explained by the model was only 12.9%. We next sought to evaluate the independent information conferred by these SNPs to the optimal clinical/demographic multivariable model for 18-month BMI change, as summarized in Table 8 . The optimal, combined clinical and genetic model in Table 8 included ADIPOR1 and FTO, both of which remained statistically significant (P < .05 for both). SNPs associated with whether or not a patient gained 0.5 BMI kg/m 2 were similar (data not shown).
Analysis of Leptin and Adiponectin Changes
Correlations of 18-month changes in adiponectin and leptin levels with 18-month BMI change were small and did not differ significantly from no correlation (correlation, 0.03 and 0.21, respectively; P > .05 for both). Adiponectin and high-molecular-weight adiponectin were significantly negatively correlated with BMI at baseline, with correlation coefficients of 20.19 (P < .001) and 20.15 (P 5 .003), respectively; and leptin was positively Abbreviations: A/C, alanine/cytosine; A/T, alanine/thymine; CI, confidence interval; FTO 1, fat mass and obesity-associated gene; rs, reference single nucleotide polymorphism number.
correlated with BMI, with a coefficient of 0.41 (P < .001). HMW/adiponectin ratios and irisin levels were not statistically significantly correlated with BMI at baseline.
Association of Dietary/Lifestyle Factors With 18-Month BMI Change
A survey of 30 diet and lifestyle questions was administered to women at baseline. Among 236 responders who had follow-up of at least 18 months, increased intake of beer and wine as well as strenuous exercise at diagnosis were statistically significantly associated with lower BMI change (P < .05 for all; data not shown). No other diet or lifestyle factors appeared to be significantly associated with weight gain.
DISCUSSION
In this prospective study of patients with newly diagnosed breast cancer, we observed that weight gain was associated with younger age at breast cancer diagnosis that and 2 obesity-related SNPs (reference SNP 10920531
[rs10920531] and rs9939609) were associated with an increased risk of breast cancer. 6, 20 Weight gain after breast cancer diagnosis is a significant health hazard because of its impact on survival, breast cancer-specific survival, and quality of life. 1, 5, 21, 22 Emerging data suggest that chemotherapy and aromatase inhibitor therapy are less effective in obese women. 23, 24 Weight loss strategies in patients with breast cancer have been associated with improved quality of life, adipokine levels, and outcomes. [25] [26] [27] [28] To our knowledge, this is the first comprehensive, prospective analysis of demographic, treatment-related, genetic, and lifestyle factors associated with weight gain in patients with newly diagnosed breast cancer.
Previous studies have demonstrated that younger age at diagnosis [29] [30] [31] is associated with increased weight gain after a breast cancer diagnosis. In our study, we were able to confirm these results. There has been disagreement regarding whether chemotherapy contributes to weight gain. 29, 30, 32, 33 In the current study, women initially lost weight during chemotherapy but then tended to gain more weight with increasing time after chemotherapy compared with women who had not received chemotherapy.
Adiponectin is an adipokine that is inversely correlated with breast cancer risk. 5, 34, 35 It plays an important role in glucose and lipid metabolism by enhancing insulin sensitivity, reducing hepatic glucose output, and increasing fatty acid oxidation. 36, 37 Furthermore, it has been demonstrated that adiponectin has antineoplastic, antiinflammatory, and antiatherogenic properties. 36, 37 Previous studies have indicated that low adiponectin levels are associated with increased breast cancer-related mortality. 38, 39 We were the first to demonstrate that functional adiponectin pathway SNPs were significantly associated with breast and colon cancer risk. 7, 8, 18, 20 In the current study, baseline adiponectin levels were inversely correlated with BMI at diagnosis; and, although serum adiponectin levels did not predict weight changes, adiponectin pathway SNPs were significantly associated with weight gain in patients with newly diagnosed breast cancer.
Leptin is another adipokine in which levels increase in obesity and in response to insulin secretion. 40 Leptin levels are positively correlated with breast cancer mortality. 41 Our past work has indicated a positive correlation between leptin levels and tumor necrosis factor a, 42 possibly explaining its role in breast cancer-related mortality. Our prospective data indicated that leptin levels were positively correlated with BMI at diagnosis but were not predictive of weight changes over 18 months.
Irisin is encoded by FNDC5 and is a myokine produced during exercise. Irisin promotes the conversion of white fat to brown fat, and lower levels have been observed in patients who have breast cancer compared with controls. 43 Two FNDC5 SNPs, rs16835198 and rs726344, have been identified that alter insulin sensitivity. 19 In our study, rs726344 was significantly associated with weight change at 18 months in univariate, but not multivariate, analysis.
We also examined the role of FTO in weight gain. It is still not fully understood how FTO is associated with obesity, and its obesity-associated properties may be related to 2 neighboring genes, RPGRIP1L and IRX3 (Iroquois homeobox 3). 44 We demonstrated that the obesityassociated variants within FTO were significantly associated with breast cancer risk. We also demonstrated that FTO is expressed in breast tissue and that there is decreased expression of FTO in breast cancer compared with normal breast epithelium. 6 In the current study, rs9939609 (which is the main SNP associated with obesity and breast cancer risk) was significantly associated with weight gain in patients who had newly diagnosed breast cancer.
Our study has several strengths and weaknesses. This was a prospectively conducted study with all risk factors and endpoints predefined. Patients were assessed by 2 study coordinators (M.S., Y.X.), and data were collected in a similar pattern for all patients. Patients were treated and followed at 1 institution, which decreased the further possibility of multi-institution variability in data collection. However, follow-up data were missing for some patients, and 60.1% had 18 months of follow-up data.
In some chronic diseases, such as type II diabetes, treatment with insulin is associated with weight gain. 45 In other chronic diseases, such as chronic renal failure and human immunodeficiency virus, in which weight loss is associated with disease progression, weight gain is a measure of successful treatment initiation with peritoneal dialysis 46 and antiretroviral agents. 47 Breast cancer is considered by many a metabolic disease; therefore, weight control is important to improve its outcomes.
In summary, our prospective study on weight changes in patients with newly diagnosed breast cancer revealed that younger age at diagnosis and obesity-related genetic polymorphisms are associated with weight gain after breast cancer diagnosis. Given the role of obesity and weight gain in breast cancer-related outcomes and quality of life, future studies will focus on targeted weightinterventional strategies in the at-risk population.
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